TY - JOUR
T1 - Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura
T2 - A randomized study
AU - Tullo, Vincenzo
AU - Valguarnera, Fabio
AU - Barbanti, Piero
AU - Cortelli, Pietro
AU - Sette, Giuliano
AU - Allais, Gianni
AU - D'Onofrio, Florindo
AU - Curone, Marcella
AU - Zava, Dario
AU - Pezzola, Deborha
AU - Benedetto, Chiara
AU - Frediani, Fabio
AU - Bussone, Gennaro
PY - 2014
Y1 - 2014
N2 - Background: Drugs for migraine attacks include triptans and NSAIDs; their combination could provide greater symptom relief. Methods: A total of 314 subjects with history of migraine, with or without aura, were randomized to frovatriptan 2.5 mg alone (Frova), frovatriptan 2.5 mgdexketoprofen 25 mg (FroDex25) or frovatriptan 2.5 mgdexketoprofen 37.5 mg (FroDex37.5) and treated at least one migraine attack. This was a multicenter, randomized, double-blind, parallel-group study. The primary end point was the proportion of pain free (PF) at two hours. Secondary end points were PF at one and four hours, pain relief (PR) at one, two, four hours, sustained PF (SPF) at 24 and 48 hours, recurrence at 48 hours, resolution of nausea, photophobia and phonophobia at two and four hours, the use of rescue medication and the judgment of the treatment. Results: The results were assessed in the full analysis set (FAS) population, which included all subjects randomized and treated for whom at least one post-dose intensity of headache was recorded. The proportions of subjects PF at two hours (primary end point) were 29% (27/93) with Frova compared with 51% (48/95 FroDex25 and 46/91 FroDex37.5) with each combination therapies (p
AB - Background: Drugs for migraine attacks include triptans and NSAIDs; their combination could provide greater symptom relief. Methods: A total of 314 subjects with history of migraine, with or without aura, were randomized to frovatriptan 2.5 mg alone (Frova), frovatriptan 2.5 mgdexketoprofen 25 mg (FroDex25) or frovatriptan 2.5 mgdexketoprofen 37.5 mg (FroDex37.5) and treated at least one migraine attack. This was a multicenter, randomized, double-blind, parallel-group study. The primary end point was the proportion of pain free (PF) at two hours. Secondary end points were PF at one and four hours, pain relief (PR) at one, two, four hours, sustained PF (SPF) at 24 and 48 hours, recurrence at 48 hours, resolution of nausea, photophobia and phonophobia at two and four hours, the use of rescue medication and the judgment of the treatment. Results: The results were assessed in the full analysis set (FAS) population, which included all subjects randomized and treated for whom at least one post-dose intensity of headache was recorded. The proportions of subjects PF at two hours (primary end point) were 29% (27/93) with Frova compared with 51% (48/95 FroDex25 and 46/91 FroDex37.5) with each combination therapies (p
KW - dexketoprofen
KW - Frovatriptan
KW - migraine attacks
KW - NSAIDs
KW - triptans
UR - http://www.scopus.com/inward/record.url?scp=84898992088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898992088&partnerID=8YFLogxK
U2 - 10.1177/0333102413515342
DO - 10.1177/0333102413515342
M3 - Article
C2 - 24363238
AN - SCOPUS:84898992088
VL - 34
SP - 434
EP - 445
JO - Cephalalgia
JF - Cephalalgia
SN - 0333-1024
IS - 6
ER -